December 22, 2014
Peter Chase

Scripps robotics engineer Peter Chase works on a drug-screening robot at the Jupiter facility.

Photo: Scripps Research Institute

Sanford-Burnham

scientists at Sanford-Burnham (Lake Nona)

Photo: Sanford Burnham

Torrey Pines

Researchers at Torrey Pines Institute for Molecular Studies (Port St. Lucie)

Photo: Torrey Pines

Ryohei Yasuda

Scientific Director Ryohei Yasuda says discoveries made at Max Planck may lead to treatments for Alzheimer’s.

Photo: Max Planck

« RETURN TO RESEARCH FLORIDA

Private Institutes

Amy Keller | 5/31/2013

The Scripps Research Institute (Jupiter)
The Scripps Research Institute and Takeda Pharmaceuticals, a Japanese drug maker, have expanded a joint research effort. Their initial collaboration in 2010 led to several breakthroughs in identifying potential compounds for neurological and psychiatric diseases. Envoy Therapeutics, a drug research company that was part of that initial collaboration, was acquired by Takeda Pharmaceuticals last November.

Sanford-Burnham (Lake Nona)
With funding from the Florida Department of Health, Sanford-Burnham has launched a new Florida Translational Research Program to help accelerate drug discovery in Florida. The program provides Florida-based scientists with access to Sanford-Burnham’s drug discovery experts and advanced technologies, including Sanford-Burnham’s compound screening platform, so they can help work on potential drugs to treat everything from cancer to diabetes to obesity.

Torrey Pines Institute for Molecular Studies (Port St. Lucie)
Torrey Pines Institute has formed a research collaboration with Envoy Therapeutics, a subsidiary of Takeda Pharmaceuticals. Under the agreement, the non-profit research center will supply Envoy with compound libraries for evaluation and validation of Envoy’s assays to identify new tools and lead compounds for future drug development.

Max Planck (Jupiter)
The Max Planck Florida Institute for Neuroscience, which opened its 100,000-sq.-ft. research facility in December, has received more than $1.2 million in recent grant funding for research into disorders ranging from epilepsy to Parkinson’s disease. Meanwhile, researchers at Max Planck investigating the causes of Alzheimer’s disease have made a major discovery that could lead to targeted treatments of the disease. Scientists have long suspected beta Amyloid, a protein fragment that forms plaques in the brains of patients with Alzheimer’s, as a culprit behind the disease. Max Planck’s researchers say their studies have shown that beta Amyloid triggers increased levels of a signaling protein called Centauran-1 that appears to cause neuronal dysfunction. Principal investigator Ryohei Yasuda says the discovery “may open up an entirely new avenue for treatments to combat this disease.”

The Vaccine and Gene Therapy Institute of Florida (Port St. Lucie)
Scientists at VCGT Florida, a non-profit research institution that focuses on the human immune system, recently received $3.6 million in NIH research grants, including a $3.17 million, 5-year grant for work on boosting anti-HIV immunity through manipulation of follicular helper T cells (Tfh) function. Dr. Elias Haddad, an associate member and part of the HIV Vaccine Group at VGTI, says the researchers are getting “close to understanding the pathology contributing to persistent HIV/AIDS infection” and the grant will shed light on dysfunction of the immune system in those infected with HIV. Earlier research by Haddad and his colleagues has shown that a major defect in Tfh cells might have some bearing on the ability of HIV infected persons to respond to vaccines. VGTI has also formed a partnership with two local hospitals, Martin Health System and Jupiter Medical Center, to conduct clinical trials on cutting edge treatments for a variety of diseases.

Tags: Healthcare, Research & Development, Technology/Innovation, Research Florida

Digital Access

DIRECT DIGITAL ACCESS
Add digital to your current subscription, purchase a single ditgital issue, or start a new subscription to Florida Trend.

TABLE OF CONTENTS
An overview of the features and articles in this month's issue of Florida Trend.

ACCESS THIS ISSUE »

Florida Business News

Florida Trend Video Pick

Benefits management trends in Florida
Benefits management trends in Florida

David Faulkenberry, president, FBMC Benefits Management, explains what benefits most employers want to offer staff and what impact the ACA has had on public sector clients so far.

Earlier Videos | Viewpoints@FloridaTrend

Ballot Box

How do you feel about the historic decision to remodel US-Cuba relations?

  • Well, it's about time!
  • I'm cautiously optimistic...
  • I'm skeptical about this at best...
  • Not in favor at all: Keep the embargo strong!

See Results

Ballot Box
Subscribe